Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

MBX Biosciences Inc. (NASDAQ:MBX) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Claiming Science magazine's breakthrough of the year in 2023 , these drugs are an absolute revelation: they give you long-lasting weight loss as long as you continue taking them .

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH),which is expected to begin in 2H 2025Phase 1 ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...